Octagos Health, a medical technology company providing AI-powered cardiac device monitoring solutions, has secured over $43 million in a series B financing round to advance an AI-driven cardiac device monitoring platform.
Founded in 2020 by Shanti Bansal, the company’s latest funding round was led by Morgan Stanley Expansion Capital, with significant support from Mucker Capital and other strategic partners.
According to the company’s announcement, the new capital infusion will support its mission to revolutionize cardiac care and comprehensive patient monitoring services using artificial intelligence (AI).
Cardiac Device Monitoring Platform
Octagos Health’s platform offers AI-enabled monitoring and data analysis for cardiac devices, including ambulatory monitors, defibrillators, pacemakers, consumer wearables, and other modalities.
Leveraging its proprietary technology, Atlas AI, the company’s platform seeks to offer high sensitivity and accuracy in detecting medically relevant events. It enables healthcare professionals to make informed, timely decisions through automated workflow to improve patient outcomes.
Additionally, the platform has customizable reporting features and integrates seamlessly with electronic health records (EHR), making it suitable for cardiology practices.
According to Dr. Shanti Bansal, cardiologist and CEO of Octagos Health, the new funding will help the company accelerate advancements to its platform, scale its commercial team, and extend services to other critical areas of cardiac care, such as consumer wearables, sleep, and ambulatory monitors.
